

Psychiatry Drug Alerts 2018 Self-Assessment Module 3: Peer Comparison

You recently participated in an ABPN-approved Self-Assessment activity relevant to your specialty and/or subspecialty. This peer comparison report provides you with feedback on your performance, relative to your peers, on the test module. In order to recognize your current knowledge base and to identify specific topics where further study may be needed, please review your answers to the following questions and compare them with those of your peers.

1) In spite of an FDA warning about risk of serotonin syndrome with concomitant use of triptans and SSRIs/SNRIs, analysis of 14 years of data showed that in >19, 000 patients who received both drug types, _____% experienced extrapyramidal symptoms.

0.01	100.00 %
0.26	0.00 %
0.61	0.00 %
1.09	0.00 %

2) Using a strict, conservative case definition, the incidence of serotonin syndrome in this population was _____ per 10,000 person-years.

0.6	100.00 %
0.89	0.00 %
1.24	0.00 %
1.83	0.00 %

3) According to a combined analysis of 5 clinical trials, mifepristone can reduce _____ symptoms in patients with psychotic depression.

Cognitive	0.00 %
Negative	0.00 %
Positive	100.00 %
Cognitive and negative	0.00 %

4) In the 5 trials analyzed, efficacy was limited to study patients who had:

A score of at least 8 on the BPRS	5.88 %
Relatively high plasma levels	76.47 %
Taken a mifepristone dosage higher than 300 mg/day	0.00 %
All of the above	17.65 %

5) In a population-based, naturalistic study in patients with schizophrenia, those who were given a stimulant prescription experienced improved functional outcomes, but this effect was largely confined to:

Patients taking concomitant benzodiazepines	0.00 %
Patients over age 50 years	0.00 %
Men	0.00 %
Women	100.00 %

6) Despite concerns that stimulants could worsen positive symptoms by increasing the availability of synaptic dopamine in the limbic system, the study findings regarding hospitalization suggest they did not.

True	100.00 %
False	0.00 %

7) In the preliminary trial in patients with bipolar disorder I, II, or NOS, _____ was effective as adjunctive treatment of bipolar depression.

Aspirin	0.00 %
Minocycline	0.00 %
Aspirin plus minocycline	100.00 %
Neither aspirin nor minocycline	0.00 %

8) Interest in drugs with anti-inflammatory activity as treatment for bipolar depression is increasing. Aspirin and minocycline were investigated in this preliminary study because they:

Penetrate the brain	0.00 %
Are well tolerated	6.25 %
Act by different anti-inflammatory mechanisms	0.00 %
All of the above	93.75 %

9) In a small randomized trial of augmentation of risperidone with fluvoxamine in patients with schizophrenia, negative symptom improvement was significantly greater with:

Placebo	0.00 %
Fluvoxamine	100.00 %

10) Among the subdomains of the Scale for the Assessment of Negative Symptoms (SANS), improvement was seen in:

Poverty of speech	0.00 %
Attention deficit	0.00 %
Curbing of interests	0.00 %
All of the above	100.00 %

11) In a systematic review and network meta-analysis of efficacy and tolerability of 21 antidepressants in major depression, all studies medications were more effective than placebo at producing response. Relative to placebo, _____ had the highest odds ratio for response.

Milnacipran	0.00 %
Escitalopram	5.88 %
Amitriptyline	94.12 %
Fluoxetine	0.00 %

12) The highest dropout rates, a study marker for acceptability, were associated with amitriptyline, clomipramine, duloxetine, fluvoxamine, reboxetine, trazodone, and:

Venlafaxine	100.00 %
Sertraline	0.00 %
Fluoxetine	0.00 %
All of the above	0.00 %

13) In this study, agents that emerged as combining a relatively high response rate and a low dropout rate included escitalopram, mirtazapine, and:

Paroxetine	0.00 %
Agomelatine	5.88 %
Sertraline	0.00 %
All of the above	94.12 %

14) Safety data were analyzed from a multinational inferiority study comparing 3-month with 1-month long-acting injectable paliperidone. The results of this analysis show that the 3-month formulation had similar rates of local pain and reactions to the 1-month formulation.

True	100.00 %
False	0.00 %